Nature Communications (Jul 2020)
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
- Lucía Barbier-Torres,
- Karen A. Fortner,
- Paula Iruzubieta,
- Teresa C. Delgado,
- Emily Giddings,
- Youdinghuan Chen,
- Devin Champagne,
- David Fernández-Ramos,
- Daniela Mestre,
- Beatriz Gomez-Santos,
- Marta Varela-Rey,
- Virginia Gutiérrez de Juan,
- Pablo Fernández-Tussy,
- Imanol Zubiete-Franco,
- Carmelo García-Monzón,
- Águeda González-Rodríguez,
- Dhaval Oza,
- Felipe Valença-Pereira,
- Qian Fang,
- Javier Crespo,
- Patricia Aspichueta,
- Frederic Tremblay,
- Brock C. Christensen,
- Juan Anguita,
- María Luz Martínez-Chantar,
- Mercedes Rincón
Affiliations
- Lucía Barbier-Torres
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Karen A. Fortner
- Department of Medicine, Immunobiology Division, University of Vermont
- Paula Iruzubieta
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Research Institute Marqués de Valdecilla (IDIVAL)
- Teresa C. Delgado
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Emily Giddings
- Department of Medicine, Immunobiology Division, University of Vermont
- Youdinghuan Chen
- Departments of Epidemiology, Pharmacology and Toxicology, and Community and Family Medicine, Geisel School of Medicine at Dartmouth
- Devin Champagne
- Department of Medicine, Immunobiology Division, University of Vermont
- David Fernández-Ramos
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Daniela Mestre
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPB/EHU. Leioa, Biocruces Health Research Institute
- Beatriz Gomez-Santos
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPB/EHU. Leioa, Biocruces Health Research Institute
- Marta Varela-Rey
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Virginia Gutiérrez de Juan
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Pablo Fernández-Tussy
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Imanol Zubiete-Franco
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Carmelo García-Monzón
- Liver Research Unit, Santa Cristina University Hospital, Instituto de Investigación Sanitaria Princesa, CIBERehd
- Águeda González-Rodríguez
- Liver Research Unit, Santa Cristina University Hospital, Instituto de Investigación Sanitaria Princesa, CIBERehd
- Dhaval Oza
- Alnylam Pharmaceuticals
- Felipe Valença-Pereira
- Department of Immunology and Microbiology, University of Colorado Denver
- Qian Fang
- Department of Immunology and Microbiology, University of Colorado Denver
- Javier Crespo
- Department of Gastroenterology and Hepatology, Marqués de Valdecilla University Hospital, Research Institute Marqués de Valdecilla (IDIVAL)
- Patricia Aspichueta
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPB/EHU. Leioa, Biocruces Health Research Institute
- Frederic Tremblay
- Alnylam Pharmaceuticals
- Brock C. Christensen
- Departments of Epidemiology, Pharmacology and Toxicology, and Community and Family Medicine, Geisel School of Medicine at Dartmouth
- Juan Anguita
- CIC bioGUNE, Inflammation and Macrophage Plasticity laboratory, Bizkaia Science and Technology Park. Derio, Bizkaia, Spain; and Ikerbasque, Basque Foundation for Science
- María Luz Martínez-Chantar
- CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas and Digestivas (CIBERehd). Bizkaia Science and Technology Park
- Mercedes Rincón
- Department of Medicine, Immunobiology Division, University of Vermont
- DOI
- https://doi.org/10.1038/s41467-020-16991-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Non-alcoholic fatty liver (NAFLD) disease causes degeneration of the liver, affects about 25% of people globally, and has no approved treatment. Here, the authors show that the therapeutic siRNA-driven silencing of MCJ in the liver is an effective and safe treatment for NAFLD in multiple mouse models.
